DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Flaherty KT, Lorusso pM, Demichele A, Abramson VG, Courtney R, Randolph SS. et al.
phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor pD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Clin Cancer Res 2012;
18: 568-76
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.